RT 12MG LY-3437943

Retatrutide is an investigational peptide-based therapeutic belonging to the class of multi-agonist molecules designed to target metabolic disorders, primarily obesity and type 2 diabetes mellitus. Structurally, it is a triple agonist that simultaneously activates the glucagon-like peptide-1 receptor (GLP-1R), glucose-dependent insulinotropic polypeptide receptor (GIPR), and glucagon receptor (GCGR), which are integral to glucose homeostasis, appetite regulation, and energy expenditure. Preclinical studies have demonstrated that this combinatorial receptor activation produces synergistic effects, including enhanced insulin secretion, suppression of glucagon overproduction, delayed gastric emptying, and increased thermogenesis, leading to substantial reductions in body weight and improvements in glycemic control. Early-phase clinical trials indicate that Retatrutide exhibits a dose-dependent effect on body weight loss in patients with obesity and overweight, surpassing the efficacy observed with single-agonist GLP-1 receptor agonists. Ongoing research is evaluating its long-term safety profile, cardiovascular outcomes, and potential benefits on hepatic steatosis, with a particular focus on understanding receptor-specific contributions to metabolic regulation and the mitigation of adverse events such as gastrointestinal intolerance and hyperglycemia.